Apollo Ventures Holding GmbH
Große Reichenstraße 27
20457 Hamburg
Nils Regge
E-Mail: info@apollo.vc
Internet address: https://www.apollo.vc
Entry in: Handelsregister
Register Number: HRB 145975
Register Court: Amtsgericht Hamburg
The contents of this website were written with due diligence and by the author’s best knowledge. We can be held liable only by general laws, especially for our own contents acc. § 7 TMG (German law on tele-media) and for external contents acc. §§ 8 – 10 TMG. As a Provider of tele-media we can be held liable for external contents only once we have knowledge of a concrete infringement of law. We reserve the right to change or delete contents of this webpage which are not subject to any contractual obligation.
Contents of external websites on which we are linking direct or indirect (through „hyperlinks“ or „deeplinks“) are beyond our responsibility and are not adopted as our own content. When the links were published, we didn’t have knowledge of any illegal activities or contents on these websites. Since we do not have any control on the contents of these websites, we distance ourselves from all contents of all linked websites, which were updated after the setting of the links. For all contents and especially damages, resulting of the use of the linked websites, only the provider of these linked websites can be held liable. If we receive knowledge of illegal contents on these linked websites, we will delete the according links.
All content of this website, are subject to copyright laws. The use, reproduction and so on are subject to the individual rights of the respective owner of the copyright or administrator of these rights. If you want to use such content, please let us know and we will establish contact with the respective owner/administrator.
The key information document for packaged retail and insurance-based investment products (PRIIPS) regarding Apollo Health Ventures Fund II GmbH & Co. KG can be found here, while the PRIIPS regarding Apollo Health Ventures Feeder II GmbH & Co. KG is available here. Das Basisinformationsblatt für verpackte Anlageprodukte für Kleinanleger und Versicherungsanlageprodukte (BIB) für die Apollo Health Ventures Fund II GmbH & Co. KG ist hier verfügbar, während das BIB für die Apollo Health Ventures Feeder II GmbH & Co. KG hier abgerufen werden kann.
Apollo Health VenturesManagement GmbH (“Apollo”) takes compliance seriously. Pursuant to Regulation (EU) 2019/2088 on sustainability‐related disclosures in the financial services sector (the Sustainable Finance Disclosure Regulation, “SFDR”), Apollo makes the following disclosures.
Apollo has adopted a process-based approach to review sustainability risks in its investment decisions. Investments made by Apollo undergo a due diligence process factoring in different aspects of a potential investments. In this process, sustainability risks are assessed and reviewed. In its decision whether to pursue an investment opportunity Apollo will – among other aspects –take the outcome of such review into consideration.
Apollo considers principal adverse impacts of its investments on sustainability factors. Apollo believes that its investment scope, focusing on certain biotechnological and digital health companies which are primarily located in Europe and the USA, generally encompasses limited adverse impacts on sustainability factors. Despite a generally low risk profile, an area of importance for Apollo is particularly environmental impacts caused by drug development programs, especially regarding manufacturing of pharmaceuticals or research in relation thereto. In many instances, these programs are conducted by external service providers.
To effectively manage sustainability impacts, Apollo works with a network of renown partners in the space and also promotes that its portfolio companies handle potential and existing sustainability impacts responsibly. Given the limited exposure to adverse effects on sustainability factors, Apollo has adopted an incidence based approach to identify and potentially address adverse impacts on sustainability. Potential adverse impacts are likely to be detected within Apollo’s portfolio activities and subsequently reported to the management board of Apollo. Apollo seeks to address any potential adverse impact on sustainability in collaboration with its portfolio companies.
As a registered alternative investment fund manager within the meaning of section 2 (4) of the KAGB and a manager of a qualifying venture capital fund as defined in article 3 (b) of the EuVECA Regulation, Apollo does not have, and does not need to have, a remuneration guideline or policy in accordance with the requirements of the regulation. Sustainability risks are not considered with respect to the determination of the remuneration.
Apollo considers certain environmental and social characteristics as part of its investment decisions but does not seek to make sustainable investments as defined in the SFDR. The consideration of environmental and social characteristics is carried out both before and after the investments. For this purpose, information is initially and regularly obtained from the portfolio companies by means of qualitative queries. Apollo incorporates exclusion (negative screening) aspects during its decision-making process.
Apollo berücksichtigt bestimmte ökologische und soziale Merkmale im Rahmen seiner Investitionsentscheidungen, strebt aber keine nachhaltigen Investitionen im Sinne der SFDR an. Die Berücksichtigung von Umwelt- und Sozialmerkmalen erfolgt sowohl vor als auch nach den Investitionen. Zu diesem Zweck werden zunächst und regelmäßig Informationen von den Portfoliounternehmen durch qualitative Abfragen eingeholt. Apollo bezieht Investitionsausschlüsse (negative Screening) in den Entscheidungsprozess ein.
This financial product promotes environmental or social characteristics (Art. 8 SFDR) but does not have as its objective a sustainable investment (Art. 9 SFDR).
This financial product does not invest in portfolio companies whose business include:
Apollo Health Ventures Fund II GmbH & Co. KG (the “Fund”) invests in biotech companies developing drugs targeting age-related diseases as well as in data analytics companies focusing on the underlying causes of age-related diseases. Companies developing medical devices shall be excluded.
The Fund intends to make its initial investments in the early stage, i.e., Seed and Series A rounds (including, for the avoidance of doubt, late seed rounds and occasionally Series B rounds). The Fund’s ESG approach (i.e., its investment exclusions) comprises part of its investment strategy, which is consistently applied for every portfolio company investment.
he Fund does not invest a fixed percentage in portfolio companies aligned with environmental and/or social characteristics but will only invest in line with its investment strategy. No portion of the Fund’s capital will be allocated to other asset classes.
Apollo has an increased awareness of the impact of sustainability risks on risk management and thus on the value potential of investments. Apollo consults with the companies on an ad-hoc basis and will carry out further checks if there are indications of potential issues with the Fund’s exclusion criteria. External monitoring mechanisms are not provided.
Currently, Apollo applies qualitative assessments with regard to environmental or social characteristics. An initial assessment is conducted in the course of the due diligence process. Such assessment takes the form of a questionnaire which we ask our portfolio companies to complete.
Information is obtained from the respective portfolio companies during the Fund’s due diligence process in which the questionnaire is completed by the portfolio companies. An external review or verification of the information obtained will only be carried out if misrepresentations are suspected.
The information collected via the due diligence proceed for the Fund is externally verified only if and to the extent misrepresentations are suspected. Thus, it cannot be ruled out completely that false information may remain undetected in certain cases. As the Fund’s investment is made for several years, Apollo considers it a priority to establish and maintain a trustful working relationship with the Fund’s portfolio companies in order to ensure compliance with the restrictions described in this section.
An initial assessment of how an investment relates to these requirements is carried out as part of the due diligence process. As a rule, purely qualitative statements of an ecological or social nature or relating to corporate governance are requested from the portfolio companies and then taken into account in the investment decision-making process.
Apollo decides at its sole discretion whether or not to make an investment based on principal adverse impacts on sustainability factors and may include risk mitigation measures where appropriate.
